Michael Gutch - Jul 16, 2021 Form 4 Insider Report for Entasis Therapeutics Holdings Inc. (ETTX)

Signature
Elizabeth M. Keiley as Attorney-in-Fact for Michael Gutch
Stock symbol
ETTX
Transactions as of
Jul 16, 2021
Transactions value $
$0
Form type
4
Date filed
2/15/2022, 03:05 PM
Previous filing
Jun 28, 2021
Next filing
Oct 20, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETTX Employee Stock Option (Right to Buy) Disposed to Issuer -30K -100% 0 Jul 16, 2021 Common Stock 30K $6.85 Direct F1, F2
transaction ETTX Employee Stock Option (Right to Buy) Award +23.1K 23.1K Jul 16, 2021 Common Stock 23.1K $2.44 Direct F3
transaction ETTX Employee Stock Option (Right to Buy) Disposed to Issuer -16K -100% 0 Jul 16, 2021 Common Stock 16K $15.00 Direct F4, F5
transaction ETTX Employee Stock Option (Right to Buy) Award +8.86K 8.86K Jul 16, 2021 Common Stock 8.86K $2.44 Direct F5, F6
transaction ETTX Employee Stock Option (Right to Buy) Disposed to Issuer -56.5K -100% 0 Jul 16, 2021 Common Stock 56.5K $5.66 Direct F7, F8
transaction ETTX Employee Stock Option (Right to Buy) Award +43.5K 43.5K Jul 16, 2021 Common Stock 43.5K $2.44 Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option will vest on December 6, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date.
F2 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,006 shares of issuer's common stock granted to the Reporting Person on May 1, 2018. In exchange, the Reporting Person received a replacement option for 23,081 shares of issuer's common stock, having an exercise price of $2.44 per share.
F3 The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.
F4 The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option shall vest on September 25, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
F5 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,956 shares of issuer's common stock granted to the Reporting Person on September 25, 2018. In exchange, the Reporting Person received a replacement option for 8,863 shares of issuer's common stock, having an exercise price of $2.44 per share.
F6 Ninety-four (94%) of this award will vest on July 16, 2022, and one-third of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.
F7 The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option shall vest on January 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
F8 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 56,500 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 43,460 shares of issuer's common stock, having an exercise price of $2.44 per share.
F9 Eighty-five (85%) of this award will vest on July 16, 2022, and one-seventh of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.

Remarks:

Chief Financial Officer and Chief Business Officer